Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis
about
Advances in rheumatology: new targeted therapeuticsRituximab for rheumatoid arthritisAdverse effects of biologics: a network meta-analysis and Cochrane overviewUpdated consensus statement on the use of rituximab in patients with rheumatoid arthritis.Rituximab for the treatment of IgG4-related orbital disease: experience from five casesWhat is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?Rituximab in autoimmune diseasesRituximab for Rheumatoid Arthritis.Recent advances in the genetics of autoimmune diseaseLeveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States.The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease.Experience with long-term rituximab use in a multiple sclerosis clinicRisk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab.Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patientsEfficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab'Rationale of using different biological therapies in rheumatoid arthritis.The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategiesRituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.Modelling cost-effectiveness of biologic treatments based on disease activity scores for the management of rheumatoid arthritis in Spain.Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study.Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis.Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology.B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseasesCost-effectiveness modelling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in Finland.Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials.Prolonged B cell depletion with rituximab is effective in treating refractory pulmonary granulomatous inflammation in granulomatosis with polyangiitis (GPA).Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunityNeutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatmentRituximab in the treatment of pemphigus vulgaris.Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective.Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients.Infectious complications associated with monoclonal antibodies and related small moleculesThe Janus of lupus--benefits and risks with B-cell therapy.Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease.Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis.Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature.Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice.Rituximab for the treatment of rheumatoid arthritis: an update.Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
P2860
Q21093257-50820442-6803-4971-9CB6-C0B68A4850A5Q24186568-2C8A5F68-7818-4802-91ED-1A8FBDBFC157Q24234197-54C67011-7C62-4EE9-81EB-857A9067B16EQ27691388-432EB3F5-1255-46FC-B2D8-E9B8F5380084Q27970312-C8E3BD3B-2897-4C8A-9E50-D5F9D72F427FQ28074148-ED2F4FA8-C0BD-42A7-B069-2DFEABC45DF1Q28076091-C246A819-4E96-4817-B88A-2E59590D3B8BQ28080246-44782363-7869-4D22-83B4-80F99537F2ACQ28238782-94D1CB5C-9769-4560-A5DC-00B55C8BCA07Q30583310-1F0AFD19-8601-45CD-894D-7333672DF2A2Q33683956-27B5637B-901F-40D9-9753-5C8347E6D86BQ33692751-67382119-E88E-4320-9FAF-F4009155D89DQ33757203-D3010DB7-994A-471A-85B1-F0863135D6C9Q33765608-65D6B759-945A-49BE-A907-4157FECD0F3EQ34056237-BB66519A-B715-4309-BEA3-0D1E52CA7AEEQ34125254-BDBB0B4F-69E8-4FF0-8541-38D424E862A2Q34153073-FDCAC9EA-8158-4D2C-8B7E-F71E6ECE0834Q34346198-EEF14E83-B110-4490-9871-28818D21917CQ34500502-AE3691C5-90FE-4B42-9236-E6B4EAB146ACQ35113679-D5FE9238-7310-48E2-9B63-FA4E16ECD9F0Q35557868-751666F8-DF28-4610-9FEE-773FF0FFB03FQ35569500-C76FDD50-8DCE-481D-ADAE-43F641B3499AQ35605474-F33DFF02-F507-4B2B-8748-E90127100E2FQ35903957-D44CF79E-9C9B-4B12-B3FA-0FAEB3B836AEQ35952231-85B859BC-E6AA-41E0-857D-C9BE89592B25Q36060036-C0830118-B4D0-4D3F-AEAA-9D2578D784F9Q36152477-C5C37D2D-EFC4-4BEA-984D-F7240D7EDC2DQ36245714-F9465B50-5164-49B7-8025-535A297E07ACQ36338254-76D86DD1-40B6-4793-9549-FE57479B938DQ36434853-B5B92920-1809-4F9D-AE45-F97047170DA3Q36633769-B5CD1B4A-83F6-46AD-A774-EB9B36E939FDQ37130018-95931FA8-A66C-4950-898F-7A406C072E33Q37156636-9BBA8682-F83D-4C10-977C-91F98A5E1529Q37168037-EE13627B-C469-4474-BCA5-4C489A097CF6Q37261621-C19AA586-D8C1-4D87-968B-07B4411139CFQ37270745-316FB371-C51F-4150-9C18-05DD6FB2A0AFQ37358271-5C8A9F05-99D1-48B3-B2D9-6B1E2EDFC2B2Q37385727-680E9BDD-CCC4-4598-AE3E-5D2034D5FB7BQ37444678-7D6D1634-F3B9-4FD7-AFB6-4E7B2A82A17EQ37633537-8E78053C-8A14-46B1-AA29-723880C13F11
P2860
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis
description
article
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в грудні 2007
@uk
name
Safety and efficacy of additio ...... open-label extension analysis
@en
Safety and efficacy of additio ...... open-label extension analysis
@nl
type
label
Safety and efficacy of additio ...... open-label extension analysis
@en
Safety and efficacy of additio ...... open-label extension analysis
@nl
prefLabel
Safety and efficacy of additio ...... open-label extension analysis
@en
Safety and efficacy of additio ...... open-label extension analysis
@nl
P2093
P50
P921
P356
P1476
Safety and efficacy of additio ...... open-label extension analysis
@en
P2093
Andrew Baldassare
Andrew Chubick
Daniel E. Furst
Edward Keystone
Fabio Magrini
James Udell
Joan Bathon
Matthew W. Cravets
Roy Fleischmann
Simon Cooper
P304
P356
10.1002/ART.23059
P577
2007-12-01T00:00:00Z